ACIU.US AC Immune Ltd

Healthcare Biotechnology USA Stocks
2.10 USD
Close of Nov 13, 2026
2.02 3.90
Market cap
USD 209M
P/E
-
P/B
6.53x
ROE
-107.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ACIU.US undervalued?

Graham number

The Graham number of AC Immune Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AC Immune Ltd fundamental analysis

No fundamental analysis for AC Immune Ltd yet.

AC Immune Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab…

Full company profile